WuXi AppTec, a global pharmaceutical, biotechnology and medical device open-access capability and technology platform, has acquired ResearchPoint Global (RPG), a U.S.-based CRO with expertise spanning across all major therapeutic areas. Upon the closing of this acquisition, RPG will become a wholly-owned subsidiary of WuXi, and will continue to focus on growing its core competences and providing better clinical development services. The acquisition underscores a strategic step forward to expand WuXi’s clinical research capabilities in the U.S. and around the world, further strengthening WuXi’s integrated R&D capability platform.
Accenture joins Partnership on AI
FDA selects Box for cloud content management
U.S. District Court issues Restasis patents trial decision
The Pulse on Site Success by Christophe Berthoux
The industry largely accepts ICH/GCP guidelines as the gold standard regarding conduct in clinical research, which was recently updated in response to the increasing use of technology as well as findings from regulatory inspections. In November 2016, the second revision to ICH Good Clinical Practices E6 R2 contained an integration of 26 new additions to serve as guidance for clinical study conduct.